PL4010082T3 - Wieloswoiste przeciwciała anty-tcr zmienne delta 1 - Google Patents
Wieloswoiste przeciwciała anty-tcr zmienne delta 1Info
- Publication number
- PL4010082T3 PL4010082T3 PL21756070.5T PL21756070T PL4010082T3 PL 4010082 T3 PL4010082 T3 PL 4010082T3 PL 21756070 T PL21756070 T PL 21756070T PL 4010082 T3 PL4010082 T3 PL 4010082T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- tcr delta
- multispecific anti
- delta variable
- variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2020/051959 WO2021032963A1 (fr) | 2019-08-16 | 2020-08-14 | Utilisations thérapeutiques d'anticorps anti-domaine variable 1 de tcr delta |
GBGB2102224.9A GB202102224D0 (en) | 2021-02-17 | 2021-02-17 | Anti-TRC delta variable 1 antibodies |
GBGB2102222.3A GB202102222D0 (en) | 2021-02-17 | 2021-02-17 | Multispecific anti-TCR delta variable 1 antibodies |
PCT/IB2021/057509 WO2022034562A1 (fr) | 2020-08-14 | 2021-08-14 | Anticorps anti-domaine variable 1 de tcr delta multispécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
PL4010082T3 true PL4010082T3 (pl) | 2023-05-29 |
Family
ID=80247426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL21756070.5T PL4010082T3 (pl) | 2020-08-14 | 2021-08-14 | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
Country Status (18)
Country | Link |
---|---|
EP (7) | EP4218932A3 (fr) |
JP (1) | JP2023537534A (fr) |
KR (1) | KR20230083267A (fr) |
CN (1) | CN116209456A (fr) |
AU (1) | AU2021323512A1 (fr) |
BR (1) | BR112023002741A2 (fr) |
CA (1) | CA3188682A1 (fr) |
CO (1) | CO2023003009A2 (fr) |
DK (1) | DK4010082T3 (fr) |
ES (1) | ES2943063T3 (fr) |
FI (1) | FI4010082T3 (fr) |
IL (1) | IL300517A (fr) |
LT (1) | LT4010082T (fr) |
MX (1) | MX2023001728A (fr) |
PL (1) | PL4010082T3 (fr) |
PT (1) | PT4010082T (fr) |
SI (1) | SI4010082T1 (fr) |
WO (1) | WO2022034562A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116209456A (zh) | 2020-08-14 | 2023-06-02 | 伽马三角洲疗法有限公司 | 多特异性抗TCRδ可变1抗体 |
WO2023250485A1 (fr) * | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Test d'activité de composés multispécifiques dépendant de lymphocytes t |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2546268A1 (fr) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Immunoglobuline s'internalisant |
WO2015063069A1 (fr) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Récepteurs antigéniques chimériques avec domaines de liaison à l'antigène dérivés des récepteurs des cellules t gamma delta |
GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
EP3307875B1 (fr) | 2015-06-09 | 2021-12-15 | Lymphact - Lymphocyte Activation Technologies, S.A. | Procédés pour la production de lymphocytes t tcr gamma delta+ |
MY198084A (en) | 2015-10-30 | 2023-07-31 | Cancer Research Tech Ltd | Expansion of non-haematopoietic tissue-resident ()()t cells and uses of these cells |
KR102519861B1 (ko) | 2016-05-12 | 2023-04-10 | 아디셋 바이오, 인크. | γδ T-세포 집단의 선택적 확장을 위한 방법 및 그의 조성물 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
EP3490675A4 (fr) | 2016-07-29 | 2020-07-29 | New York University | Lymphocytes t gamma delta utilisés comme cible pour le traitement de tumeurs solides |
US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
JP7356970B2 (ja) | 2017-06-25 | 2023-10-05 | システィミューン, インク. | 多重特異性抗体とその作製及び使用方法 |
EP3743081A4 (fr) | 2018-01-23 | 2021-12-01 | New York University | Anticorps spécifiques de la chaîne delta 1 du récepteur des lymphocytes t |
US20210371525A1 (en) * | 2018-09-19 | 2021-12-02 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
WO2020159368A1 (fr) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Nouveaux anticorps se liant au cd40 |
JP2022525435A (ja) | 2019-04-08 | 2022-05-13 | メモリアル スローン ケタリング キャンサー センター | Cd19抗体およびこれを使用する方法 |
CA3145523A1 (fr) * | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Utilisations therapeutiques d'anticorps anti-domaine variable 1 de tcr delta |
US20220290101A1 (en) | 2019-08-16 | 2022-09-15 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
CN116209456A (zh) | 2020-08-14 | 2023-06-02 | 伽马三角洲疗法有限公司 | 多特异性抗TCRδ可变1抗体 |
WO2022175414A1 (fr) | 2021-02-17 | 2022-08-25 | Adaptate Biotherapeutics Ltd. | Anticorps multispécifiques anti-domaine delta 1 variable de tcr |
-
2021
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/fr active Pending
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 EP EP21756070.5A patent/EP4010082B1/fr active Active
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/fr active Active
- 2021-08-14 CA CA3188682A patent/CA3188682A1/fr active Pending
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/fr active Active
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 JP JP2023510439A patent/JP2023537534A/ja active Pending
- 2021-08-14 ES ES21756070T patent/ES2943063T3/es active Active
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 DK DK21756070.5T patent/DK4010082T3/da active
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 PL PL21756070.5T patent/PL4010082T3/pl unknown
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/fr active Active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko unknown
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T3/fi active
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/fr active Application Filing
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/fr active Active
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/fr active Active
-
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3872091T1 (sl) | Protitelesa proti SARS-COV-2 | |
IL290537A (en) | Therapeutic uses of anti-tcr variable delta 1 antibodies | |
IL292727A (en) | Multispecific antibodies | |
SI4010082T1 (sl) | Multispecifična protitelesa anti-TCR delta variable 1 | |
EP3941944A4 (fr) | Anticorps de claudin-6 bispécifiques | |
IL308741A (en) | Anti-SIRP-alpha antibodies | |
GB202010652D0 (en) | Anti-tau antibodies | |
GB202102222D0 (en) | Multispecific anti-TCR delta variable 1 antibodies | |
GB202203226D0 (en) | Trays | |
GB202111685D0 (en) | Anti-tcr delta variable 1 antibodies | |
IL300142A (en) | Anti-IL13Ralpha2 antibodies | |
GB202105110D0 (en) | Anti-CD73 antibodies | |
GB202014851D0 (en) | SARS-COV-2 antibodies | |
GB202102224D0 (en) | Anti-TRC delta variable 1 antibodies | |
EP4062084A4 (fr) | Courroie pour transmission à variation continue | |
GB201901045D0 (en) | Variable wheelbase combine | |
IL307332A (en) | New multispecific antibodies | |
IL311043A (en) | Anti-IL---11RA antibodies | |
IL310245A (en) | Anti-HLA-G antibodies | |
GB202208773D0 (en) | Anti-SARS2-S antibodies | |
IL308782A (en) | Antibodies | |
IL308100A (en) | Antibodies | |
IL307175A (en) | IL-38 specific antibodies | |
GB202116709D0 (en) | Antibodies | |
GB202115824D0 (en) | Antibodies |